Photo of Justin Pritchard

Justin Pritchard

Assistant Professor

Affiliation(s):

  • Biomedical Engineering

212 Wartik Building

jrp94@psu.edu

814-865-7906

Personal or Departmental Website

Research Areas:

Cell and Molecular Bioengineering; Cell Signaling and Cancer

Interest Areas:

Systems Biology, Synthetic Biology, Drug Resistance

 
 

 

Education

  • BS, Biology, University of California, Los Angeles, 2006
  • Ph D, Computational and Systems Biology, Massachusetts Institute of Technology, 2012

Publications

Journal Articles

  • Laura Laencina, Violaine Dubois, Vincent Le Moigne, Albertus Viljoen, Laleh Majlessi, Justin Pritchard, Audrey Bernut, Laura Piel, Anne-Laure Roux, Jean-Louis Gaillard, Jean-Lois Herrmann and Fabienne Girard-Misguich, 2018, "Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus", Proceedings of the National Academy of Sciences, pp. 201713195
  • Joseph M Gozgit, Tzu-Hsiu Chen, Youngchul Song, Scott Wardwell, Frank Wang, Jie Cai, Henry Li, Henrik Edgren, Victor M Rivera and Justin Pritchard, 2018, "RET fusions observed in lung and colorectal cancers are sensitive to ponatinib", Oncotarget, 9, (51), pp. 29654
  • Michael W Schmitt, Justin Pritchard, Scott M Leighow, Bella I Aminov, Lan Beppu, Daniel S Kim, J Graeme Hodgson, Victor M Rivera, Lawrence A Loeb and Jerald P Radich, 2018, "Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias", Clinical Cancer Research, 24, (21), pp. 5321--5334
  • Peter M Bruno, Yunpeng Liu, Ga Young Park, Yunko Murai, Catherine Koch, Timothy J Eisen, Justin Pritchard, Yves Pommier, Stephen J Lippard and Michael Hemann, 2017, "A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress", Nature Medicine, 23, pp. 461-471
  • Jeremy Rock, Forest Hopkins, A Chavez, M Diallo, MR Chase, Elias Merrick, Justin Pritchard, Eric Rubin, George Church and Sarah Fortune, 2017, "Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.", Nature Microbiology, 2, (4), pp. 16274
  • Boyang Zhao and Justin Pritchard, 2016, "Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes", Plos Genetics, 12, (6), pp. e1006081
  • Boyang Zhao, Joseph C Sedlak, Raja Srinivas, Pau Creixell, Justin Pritchard, Bruce Tidor, Douglas A Lauffenburger and Michael T Hemann, 2016, "Exploiting temporal collateral sensitivity in tumor clonal evolution", Cell, 165, (1), pp. 234--246
  • Theresa Baker, Sujata Nerle, Justin Pritchard, Boyang Zhao, Victor M Rivera, Andrew Garner and Francois Gonzalvez, 2015, "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors", Oncotarget, 6, (32), pp. 32646
  • Corbin E Meacham, Lee N Lawton, Yadira M Soto-Feliciano, Justin Pritchard, Brian A Joughin, Tobias Ehrenberger, Nina Fenouille, Johannes Zuber, Richard T Williams, Richard A Young and others, 2015, "A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth", Genes & development, 29, (5), pp. 483–488
  • Zhao Boyang, Justin Pritchard, Douglas Lauffenburger and Michael Hemann, 2014, "Minimization of intra-tumoral heterogeneity through rationally designed combination therapy.", Cancer Discovery, 4, (2), pp. 166-174
  • Joyce Wang, Justin Pritchard, Louis Kreitmann, Alexandre Montpetit and Marcel A Behr, 2014, "Disruption of Mycobacterium avium subsp. paratuberculosis-specific genes impairs in vivo fitness", BMC genomics, 15, (1), pp. 415
  • Justin Pritchard, Michael C Chao, Sören Abel, Brigid M Davis, Catherine Baranowski, Yanjia J Zhang, Eric J Rubin and Matthew K Waldor, 2014, "ARTIST: high-resolution genome-wide assessment of fitness using transposon-insertion sequencing", PLoS genetics, 10, (11), pp. e1004782
  • Boyang Zhao, Justin Pritchard, Douglas A Lauffenburger and Michael T Hemann, 2014, "Addressing genetic tumor heterogeneity through computationally predictive combination therapy", Cancer discovery, 4, (2), pp. 166--174
  • Justin Pritchard, Peter M Bruno, Luke A Gilbert, Kelsey L Capron, Douglas A Lauffenburger and Michael T Hemann, 2013, "Defining principles of combination drug mechanisms of action", Proceedings of the National Academy of Sciences, 110, (2), pp. E170--E179
  • Michael C Chao, Justin Pritchard, Yanjia J Zhang, Eric J Rubin, Jonathan Livny, Brigid M Davis and Matthew K Waldor, 2013, "High-resolution definition of the Vibrio cholerae essential gene set with hidden Markov model–based analyses of transposon-insertion sequencing data", Nucleic acids research, 41, (19), pp. 9033–9048
  • Justin Pritchard, Peter M Bruno, Michael T Hemann and Douglas A Lauffenburger, 2013, "Predicting cancer drug mechanisms of action using molecular network signatures", Molecular BioSystems, 9, (7), pp. 1604–1619
  • Justin Pritchard, 2012, "Understanding resistance to combination chemotherapy", Drug Resistance Updates, 15, (5), pp. 249-257
  • Justin Pritchard, 2011, "BCL-2 family genetic profiling reveals microenvironment-specific determinants of therapeutic response.", Cancer Research, 71, (17), pp. 1014-1022
  • Hai Jiang, Justin Pritchard, Richard T Williams, Douglas A Lauffenburger and Michael T Hemann, 2011, "A mammalian functional-genetic approach to characterizing cancer therapeutics", Nature chemical biology, 7, (2), pp. 92–100
  • Justin Pritchard, Benjamin D Cosgrove, Michael T Hemann, Linda G Griffith, Jack R Wands and Douglas A Lauffenburger, 2009, "Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death", Molecular cancer therapeutics, 8, (8), pp. 2183–2192
  • Benjamin D Cosgrove, Connie Cheng, Justin Pritchard, Donna B Stolz, Douglas A Lauffenburger and Linda G Griffith, 2008, "An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-$\alpha$", Hepatology, 48, (1), pp. 276--288

Abstracts

  • Justin Pritchard, Michael W Schmitt, J Graeme Hodgson, Stephanie Lustgarten, Shijie Tang, Lawrence A Loeb, Jerald P Radich and Victor M Rivera, 2016, "Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib", Blood
  • Michael W Schmitt, Jesse J Salk, Edward J Fox, Justin Pritchard, J Graeme Hodgson, Victor M Rivera, Pamela S Becker, Jerald P Radich and Lawrence A Loeb, 2016, "Direct assessment of sequence heterogeneity in human cancers by Duplex Sequencing"
  • Victor M Rivera, Susan Branford, Franck E Nicolini, Justin Pritchard, Joseph M Gozgit, Wolfgang Kern, Dragana Milojkovic, Simone Claudiani, Martin C Muller, Srinivas K Tantravahi and others, 2015, "A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients"
  • Peter M Bruno, Ga Young Park, Junko Murai, Yunpeng Liu, Justin Pritchard, Yves Pommier, Stephen J Lippard and Michael T Hemann, 2015, "Abstract C56: Platinum containing anti-cancer agents as targeted therapeutics"
  • Justin Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, Jorge E Cortes, Michael W Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P Hughes, Neil P Shah and others, 2015, "High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial", Clinical Lymphoma, Myeloma and Leukemia, 15, pp. S212
  • Victor M Rivera, Susan Branford, Franck E Nicolini, Justin Pritchard, Joseph M Gozgit, Wolfgang Kern, Dragana Milojkovic, Simone Claudiani, Martin C Muller, Srinivas K Tantravahi and others, 2015, "A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients"
  • Michael W Schmitt, Justin Pritchard, Graeme Hodgson, Victor M Rivera, Bella I Aminov, Lan Beppu, Lawrence A Loeb and Jerald P Radich, 2015, "Emergence of sub-clonal drug resistance mutations during CML therapy"
  • Justin Pritchard, S Lustgarten, JG Hodgson, M Baccarani, JE Cortes, MW Deininger, F Guilhot, TP Hughes, NP Shah, M Talpaz and others, 2015, "Analysis of the relationship between dose and BCR-ABL halving time in CP-CML patients treated with ponatinib or imatinib", 100, pp. 448–449
  • Michael C Heinrich, J Graeme Hodgson, Margaret von Mehren, George D Demetri, Jonathan A Fletcher, Jichao G Sun, Justin Pritchard, Sen Zhang, Victor M Rivera and Suzanne George, 2015, "Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST)."
  • Justin Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, Jorge E Cortes, Michael W Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P Hughes, Neil P Shah and others, 2015, "High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial", Clinical Lymphoma, Myeloma and Leukemia, 15, pp. S212
  • Victor M Rivera, Justin Pritchard, Francois Gonzalvez, Theresa Baker, Joseph M Gozgit and Graeme Hodgson, 2014, "Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events"
  • Justin Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, Jorge E Cortes, Michael W Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P Hughes, Neil P Shah and others, 2014, "High-resolution analysis of the relationship between dose and molecular response in CP-CML patients treated with ponatinib or imatinib"

Other

  • Hai Jiang, Justin Pritchard, Douglas A Lauffenburger and Michael Hemann, 2017, "RNAi-based method of drug screening and characterization"
  • Justin Pritchard, Douglas A Lauffenburger and Michael Hemann, 2017, "RNAi-based method of screening and characterizing drug combinations"
  • Francois Gonzalvez, Theresa A Baker, Justin Pritchard, Victor M Rivera and Andrew Garner, 2015, "EZH2 D1 domain mutants confer acquired resistance to EZH2-targeted inhibitors and reprogram B-cell transcription"
  • Douglas A Lauffenburger, Boyang Zhao, Justin Pritchard and Michael T Hemann, 2013, "Abstract IA10: Targeting intratumoral genetic heterogeneity through rationally designed combination therapy"
  • Douglas A Lauffenburger, Justin Pritchard and Michael T Hemann, 2012, "Abstract SY22-02: Mammalian functional genetic signatures identify efficacy landscapes of combination chemotherapy"

Research Projects

Honors and Awards

Service

Service to Penn State:

Service to External Organizations:

 


 

About

The Department of Biomedical Engineering administers the undergraduate major in biomedical engineering, and is a part of the university-wide Intercollege Graduate Degree Program, offering both M.S. and Ph.D. degrees in Bioengineering. Our work combines traditional engineering principles with medicine and technology for the betterment of human health and society. 

Department of Biomedical Engineering

122 Chemical and Biomedical Engineering Building

The Pennsylvania State University

University Park, PA 16802-4400

Phone: 814-863-6614